The global multi-infarct dementia market is expected to witness growth owing to the rising prevalence of strokes and blockage in brain nerves. The multi-infarct dementia is a series of minor brain strokes, which results in the disruption of blood flow in the brain. It is also termed as vascular dementia (VaD). According to the National Institute of Health, the second largest form of dementia is multi-infarct dementia, which accounts for the maximum cases of people who are above the age of 65. Thus, increasing the geriatric population base worldwide is also propelling the global multi-infarct dementia market. Various technological advancements in several inhibitors used for the prevention of dementia is another notable factor expected to further fuel the global multi-infarct dementia market over the forecast period. However, the unavailability of treatment for reversing the brain cell damage due to stroke along with the primary focus of therapy on prevention and control of future strokes is expected to restrain the growth of the multi-infarct dementia market over the next few years.
The entire multi-infarct dementia market on the basis of treatment is segmented into pharmacological and non-pharmacological treatment. The pharmacological treatment for dementia includes cholinesterase inhibitors such as rivastigmine, galantamine, and donepezil. Revastigmine inhibitor has the capacity to inhibit both butyrylcholinesterase and acetylcholinesterase. It is termed as a second-generation cholinesterase inhibitor. Other pharmacological medications include Cytidine 5’-Diphosphocholine, folic acid, hydergine, nimodipine, and memantine. Other drugs used for the treatment of multi infarct dementia are angiotensin-converting enzyme inhibitors (ACE inhibitors), calcium channel blockers (CCBs), and selective serotonin reuptake inhibitors (SSRIs). Non-pharmacological treatment segment is expected to witness low growth over the next few years due to the low prognosis and survival rate of patients.
Geographically, the overall multi-infarct dementia market is segmented into North America, Asia Pacific, Europe, Latin America, and MEA. As of 2014, North America held the largest market share in terms of revenue owing to the increasing incidences of multi infarct dementia coupled with increasing geriatric population base. European market displayed similar traits and followed the North American multi infarct dementia market. Asia Pacific is expected to grow at a high pace due to increasing awareness about the prevention of brain strokes in this region. Japan owing to an increased geriatric base represents approximately more than 50% of the dementia cases in the Asia Pacific. The developed nations such as Japan, Canada, France, Germany, and the U.S. are anticipated to witness favorable growth over the forecast period.
Various players in the multi-infarct dementia market are adopting several competitive strategies such as collaborations, expansions, and acquisitions to keep a strong foothold and gain an advantage in the market. Some major players in the market include Forest Laboratories, Inc., Janssen Pharmaceuticals, Inc., Novartis Pharmaceutical Corporation, Pfizer, Inc., and Eisai, Inc.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.